JP2020100630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020100630A5 JP2020100630A5 JP2020019337A JP2020019337A JP2020100630A5 JP 2020100630 A5 JP2020100630 A5 JP 2020100630A5 JP 2020019337 A JP2020019337 A JP 2020019337A JP 2020019337 A JP2020019337 A JP 2020019337A JP 2020100630 A5 JP2020100630 A5 JP 2020100630A5
- Authority
- JP
- Japan
- Prior art keywords
- ofatumumab
- multiple sclerosis
- during
- administered
- regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002450 ofatumumab Drugs 0.000 claims description 47
- 238000012423 maintenance Methods 0.000 claims description 17
- 201000006417 multiple sclerosis Diseases 0.000 claims description 15
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 230000003902 lesion Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374986P | 2016-08-15 | 2016-08-15 | |
| US62/374,986 | 2016-08-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550539A Division JP6851391B2 (ja) | 2016-08-15 | 2017-08-11 | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020100630A JP2020100630A (ja) | 2020-07-02 |
| JP2020100630A5 true JP2020100630A5 (enExample) | 2020-09-24 |
| JP7198786B2 JP7198786B2 (ja) | 2023-01-04 |
Family
ID=59901554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550539A Active JP6851391B2 (ja) | 2016-08-15 | 2017-08-11 | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
| JP2020019337A Active JP7198786B2 (ja) | 2016-08-15 | 2020-02-07 | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550539A Active JP6851391B2 (ja) | 2016-08-15 | 2017-08-11 | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US11161909B2 (enExample) |
| EP (5) | EP4252847A3 (enExample) |
| JP (2) | JP6851391B2 (enExample) |
| KR (2) | KR20200136503A (enExample) |
| CN (5) | CN120053639A (enExample) |
| AU (2) | AU2017311664C1 (enExample) |
| CA (2) | CA3101514A1 (enExample) |
| CY (1) | CY1123350T1 (enExample) |
| DE (1) | DE202017007542U1 (enExample) |
| DK (2) | DK3733712T3 (enExample) |
| ES (2) | ES2954259T3 (enExample) |
| FI (1) | FI3733712T3 (enExample) |
| HR (2) | HRP20230894T1 (enExample) |
| HU (2) | HUE051948T2 (enExample) |
| IL (4) | IL276890B2 (enExample) |
| LT (2) | LT3497132T (enExample) |
| MX (1) | MX388593B (enExample) |
| PL (2) | PL3497132T3 (enExample) |
| PT (2) | PT3497132T (enExample) |
| RS (2) | RS64541B1 (enExample) |
| RU (1) | RU2749951C2 (enExample) |
| SI (2) | SI3497132T1 (enExample) |
| TW (1) | TWI752995B (enExample) |
| WO (1) | WO2018033841A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4252847A3 (en) | 2016-08-15 | 2023-11-15 | Novartis AG | Regimens and methods of treating multiple sclerosis using ofatumumab |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| JP7794735B2 (ja) | 2019-09-11 | 2026-01-06 | ノバルティス アーゲー | 切替え療法によるｒｍｓの治療 |
| WO2021204994A1 (en) * | 2020-04-09 | 2021-10-14 | Novartis Ag | Ofatumumab for treating ms while maintaining serum igg |
| CN117529336A (zh) * | 2021-04-14 | 2024-02-06 | 诺华股份有限公司 | 用于治疗亚洲患者的多发性硬化症的奥法木单抗 |
| WO2026099463A1 (en) | 2024-11-08 | 2026-05-15 | Novartis Ag | Glycoengineered anti-cd20 antibodies |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4816401A (en) | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| MXPA02009523A (es) | 2000-03-30 | 2003-02-12 | Amgen Inc | Moleculas similares a cd20/receptor de ige y usos de las mismas. |
| IL154751A0 (en) | 2000-08-03 | 2003-10-31 | Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals | |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 １가 항체 및 그의 제조 방법 |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
| AR082436A1 (es) | 2010-08-02 | 2012-12-05 | Sanofi Aventis Us Llc | Uso de teriflunomida para tratar la esclerosis multiple |
| EP2663331A4 (en) * | 2011-01-10 | 2015-07-15 | Glaxosmithkline Intellectual Property Man Ltd | NEW USES |
| WO2013120012A2 (en) | 2012-02-08 | 2013-08-15 | Igm Biosciences Inc. | Cdim binding proteins and uses thereof |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| CN104603124B (zh) | 2012-08-10 | 2018-04-17 | 勃林格殷格翰国际有限公司 | 用作布鲁顿酪氨酸激酶(btk)抑制剂的杂芳族化合物 |
| WO2015162504A1 (en) | 2014-04-23 | 2015-10-29 | Novartis Ag | Novel dosing and uses of ofatumumab |
| HK1231413A1 (zh) | 2014-04-29 | 2017-12-22 | Teva Pharmaceutical Industries Ltd. | 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德 |
| EP3250927B1 (en) * | 2015-01-28 | 2020-02-19 | H. Hoffnabb-La Roche Ag | Gene expression markers and treatment of multiple sclerosis |
| CN106699886A (zh) | 2015-07-13 | 2017-05-24 | 西藏海思科药业集团股份有限公司 | 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体 |
| EP4252847A3 (en) | 2016-08-15 | 2023-11-15 | Novartis AG | Regimens and methods of treating multiple sclerosis using ofatumumab |
| US20220389109A1 (en) | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| JP7794735B2 (ja) | 2019-09-11 | 2026-01-06 | ノバルティス アーゲー | 切替え療法によるｒｍｓの治療 |
| WO2021204994A1 (en) | 2020-04-09 | 2021-10-14 | Novartis Ag | Ofatumumab for treating ms while maintaining serum igg |
| CN117529336A (zh) | 2021-04-14 | 2024-02-06 | 诺华股份有限公司 | 用于治疗亚洲患者的多发性硬化症的奥法木单抗 |
| JP2024531314A (ja) | 2021-08-16 | 2024-08-29 | ノバルティス アーゲー | 小児ｍｓを治療するためのオファツムマブ |
-
2017
- 2017-08-11 EP EP23172507.8A patent/EP4252847A3/en not_active Withdrawn
- 2017-08-11 CN CN202510270961.2A patent/CN120053639A/zh active Pending
- 2017-08-11 EP EP25225892.6A patent/EP4711008A3/en active Pending
- 2017-08-11 IL IL276890A patent/IL276890B2/en unknown
- 2017-08-11 FI FIEP20180938.1T patent/FI3733712T3/fi active
- 2017-08-11 KR KR1020207034140A patent/KR20200136503A/ko not_active Ceased
- 2017-08-11 CN CN201780049932.7A patent/CN109641965A/zh active Pending
- 2017-08-11 LT LTEP17768863.7T patent/LT3497132T/lt unknown
- 2017-08-11 RS RS20230635A patent/RS64541B1/sr unknown
- 2017-08-11 DK DK20180938.1T patent/DK3733712T3/da active
- 2017-08-11 US US16/324,619 patent/US11161909B2/en active Active
- 2017-08-11 DE DE202017007542.3U patent/DE202017007542U1/de active Active
- 2017-08-11 EP EP24166956.3A patent/EP4371611B1/en active Active
- 2017-08-11 SI SI201730400T patent/SI3497132T1/sl unknown
- 2017-08-11 RU RU2019107146A patent/RU2749951C2/ru active
- 2017-08-11 HU HUE17768863A patent/HUE051948T2/hu unknown
- 2017-08-11 CA CA3101514A patent/CA3101514A1/en active Pending
- 2017-08-11 DK DK17768863.7T patent/DK3497132T3/da active
- 2017-08-11 KR KR1020197007454A patent/KR20190038914A/ko not_active Ceased
- 2017-08-11 CN CN202510270924.1A patent/CN120000782A/zh active Pending
- 2017-08-11 PL PL17768863T patent/PL3497132T3/pl unknown
- 2017-08-11 HR HRP20230894TT patent/HRP20230894T1/hr unknown
- 2017-08-11 IL IL313932A patent/IL313932A/en unknown
- 2017-08-11 EP EP20180938.1A patent/EP3733712B1/en active Active
- 2017-08-11 RS RS20201066A patent/RS60807B1/sr unknown
- 2017-08-11 HU HUE20180938A patent/HUE063625T2/hu unknown
- 2017-08-11 JP JP2018550539A patent/JP6851391B2/ja active Active
- 2017-08-11 MX MX2019001860A patent/MX388593B/es unknown
- 2017-08-11 AU AU2017311664A patent/AU2017311664C1/en active Active
- 2017-08-11 CN CN202510270941.5A patent/CN120053638A/zh active Pending
- 2017-08-11 CN CN202510270903.XA patent/CN120037367A/zh active Pending
- 2017-08-11 ES ES20180938T patent/ES2954259T3/es active Active
- 2017-08-11 PL PL20180938.1T patent/PL3733712T3/pl unknown
- 2017-08-11 SI SI201731396T patent/SI3733712T1/sl unknown
- 2017-08-11 ES ES17768863T patent/ES2821924T3/es active Active
- 2017-08-11 WO PCT/IB2017/054909 patent/WO2018033841A1/en not_active Ceased
- 2017-08-11 PT PT177688637T patent/PT3497132T/pt unknown
- 2017-08-11 HR HRP20201388TT patent/HRP20201388T1/hr unknown
- 2017-08-11 LT LTEP20180938.1T patent/LT3733712T/lt unknown
- 2017-08-11 IL IL302488A patent/IL302488B2/en unknown
- 2017-08-11 EP EP17768863.7A patent/EP3497132B1/en active Active
- 2017-08-11 CA CA3030530A patent/CA3030530C/en active Active
- 2017-08-11 PT PT201809381T patent/PT3733712T/pt unknown
- 2017-08-15 TW TW106127565A patent/TWI752995B/zh active
-
2019
- 2019-02-12 IL IL264804A patent/IL264804B/en active IP Right Grant
-
2020
- 2020-02-07 JP JP2020019337A patent/JP7198786B2/ja active Active
- 2020-02-17 AU AU2020201112A patent/AU2020201112C1/en active Active
- 2020-09-11 CY CY20201100861T patent/CY1123350T1/el unknown
-
2021
- 2021-10-06 US US17/495,559 patent/US20220081488A1/en not_active Abandoned
-
2023
- 2023-06-08 US US18/331,701 patent/US12570754B2/en active Active
-
2024
- 2024-03-06 US US18/597,624 patent/US12338290B2/en active Active
-
2025
- 2025-05-28 US US19/221,422 patent/US20250289902A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2762250T5 (es) | Tratamiento combinado del cáncer | |
| CA2926771C (en) | Cancer treatment with combination of plinabulin and taxane | |
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| JP2017132791A (ja) | 組み合わせ組成物 | |
| JP7818412B2 (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| JP2024129140A5 (enExample) | ||
| JP2019511506A5 (enExample) | ||
| JP2020500864A5 (enExample) | ||
| JP2022543136A5 (enExample) | ||
| CN115381939A (zh) | 治疗霍奇金淋巴瘤的药物组合物及其用途 | |
| JP2005525409A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| JP2019506397A5 (enExample) | ||
| DK202530540A1 (en) | Semaglutide in medical therapy including weight management | |
| WO2022131919A1 (en) | Acth in the treatment of an adrenocorticotropic hormone responsive pediatric disorder | |
| US20250304696A1 (en) | Methods and compositions for treating barth syndrome | |
| Chaplin et al. | Plegridy for the treatment of RRMS in adults | |
| JP2024517204A5 (enExample) | ||
| JP2025084047A (ja) | 神経内分泌腫瘍又はソマトスタチン受容体を高発現する他の腫瘍に対するルテチウム－１７７ｄｏｔａｔｏｃペプチド受容体放射性核種療法の投与のための安全で効果的なプラットフォームの開発 | |
| US20260097063A1 (en) | Anti-c5 antibody/c5 irna dosing regimens for treating c5-associated diseases | |
| CA3082625C (en) | Methods of using and compositions containing dulaglutide | |
| WO2019211829A1 (en) | Compositions and methods for treating glioblastoma | |
| WO2020160813A1 (en) | Method of treatment and pharmaceutical dosage form | |
| AU2024357712A1 (en) | Extended dosing regimens for anti-cd20 antibodies in the treatment of multiple sclerosis | |
| TW201728338A (zh) | 免疫球蛋白ｇ組合物 | |
| TH2201001953A (th) | การรักษาของโรคตับอักเสบจากแอลกอฮอล์ |